Olfactive Biosolutions Granted Third Dual GLP-1 / GIP Patent to Repurpose Food Molecules for Weight Management and Blood Sugar Regulation
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a third patent for inducing the secretion of GLP-1 and GIP, in U.S. patent US 12,171,727 B1 dated Dec. 24, 2024, Compositions and Methods for Treating Endocrine Diseases and Disorders. The patent specifically relates to oral formulations of natural food molecules for treating diabetes mellitus and obesity by modulating ectopic olfactory, taste and related receptor activity.
Olfactive Biosolutions Begins Production of Patented GLP-1/GIP Weight Loss and Blood Sugar Reduction Supplement
Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has begun production of its Protenx™ GLP-1/GIP Weight Loss patented weight loss and blood sugar reduction formulation under its U.S. patent US 12,102,664.
Olfactive Biosolutions Establishes Scientific Advisory Board
Olfactive Biosolutions, the leader in harnessing food molecules for the treatment of chronic diseases, has announced the formation of its Scientific Advisory Board. This board comprises esteemed experts in biotechnology, olfaction, drug discovery, and artificial intelligence, and will drive the company’s health and wellness innovations. Members have strong track records of innovation in drug discovery, synthetic biology, cellular assays, and chemical analysis.
Olfactive Biosolutions Granted Second GLP-1 Patent to Repurpose Food Molecules for Weight Loss and Blood Sugar Reduction
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted a second patent for inducing the secretion of GLP-1, in U.S. patent US 12,115,134 B2 dated Oct. 15, 2024, Compositions and Methods for Treating Endocrine Diseases and Disorders.
Olfactive Biosolutions Granted Patent to Repurpose Food Molecules for Treatment of Hypertension
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent 12,102,611, Compositions And Methods For Treating Hypertension By Modulating Endocrine Activity, for its breakthrough food ingredient formulation that reduces high blood pressure. Protenx™ Blood Pressure can reduce blood pressure without the side effects and drawbacks of current pharmaceutical solutions, using food molecules from the FDA-approved GRAS (Generally Recognized As Safe) list.
Olfactive Biosolutions Granted Patent to Repurpose Food Molecules for Weight Loss and Blood Sugar Reduction
Olfactive Biosolutions, the leader in adapting food molecules to treat chronic diseases, was recently granted U.S. patent US 12,102,664 B2 for its breakthrough food ingredient formulation for weight loss and blood sugar reduction. Olfactive Biosolutions’ Protenx™ Weight Loss activates olfactory receptors in the gut to induce the dual secretion of natural GLP-1 and GIP to facilitate weight loss and a significant reduction in blood sugar.
Olfactive Biosolutions Files Patent to Repurpose Food Molecules to Safely, Inexpensively Regulate Blood Pressure
Olfactive Biosolutions, the creator of the new, food molecule-based approach to healthcare, recently filed a U.S. patent for proprietary food ingredient formulations to control blood pressure without prescription pharmaceuticals and with few, if any, side effects. Protenx™ for blood pressure joins the expanding line of Protenx products, which already features innovative products to control weight and regulate blood sugar.
Olfactive Biosolutions Files Patent to Repurpose Food Molecules for Weight Loss
Olfactive Biosolutions, a leader in ectopic and chemosensory receptor technology, recently filed a U.S. patent for Protenx, a proprietary line of breakthrough food ingredient formulations. The Protenx weight loss formula for example activates the same dual GLP-1 and GIP pathways as tirzepatide, to facilitate weight loss and blood sugar regulation. Protenx weight loss formula integrates into consumer products, bringing to them the potential of achieving benefits consistent with current weight loss prescription-only pharmaceuticals.
